Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management

Core Viewpoint - Vivani Medical, Inc. is advancing its NPM-139 semaglutide implant program, aiming for Wegovy-level efficacy with less frequent administration, and plans to initiate a Phase 1 clinical study in the first half of 2026, pending regulatory clearance [1][2][3] Company Overview - Vivani Medical, Inc. is a clinical-stage biopharmaceutical company focused on developing ultra long-acting drug implants using its proprietary NanoPortal™ technology [5] - The company is developing a portfolio of GLP-1 based implants targeting chronic weight management and other metabolic diseases, including type 2 diabetes [5] Clinical Development Plans - The Phase 1 study of NPM-139 will assess safety, tolerability, and pharmacokinetics in obese or overweight subjects, with a control arm of low-dose Wegovy injections [3][4] - A Phase 2 study is planned to follow the Phase 1 study, pending results, to evaluate the effects of the semaglutide implant on weight management over 4 to 6 months [4] Market Potential - The GLP-1 market for weight management is experiencing significant growth due to unmet medical needs and improved safety and efficacy profiles of current GLP-1 options compared to previous obesity treatments [2] - NPM-139 is expected to differentiate itself by offering a convenient administration schedule of once or twice a year, potentially improving patient adherence and tolerability [2][6]